Exagamglogene Autotemcel Suspension (Casgevy)
The U.S. Food and Drug Administration has approved the first treatment for sickle cell disease using CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR associated protein 9) genome editing technology.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.